Compare Expeditors International of Wshngtn Inc (EXPD) vs Eli Lilly And Co (LLY) Price & Performance

EXPD trades at $193.71, up 1.5% with a bullish technical signal supported by moving averages. The company demonstrates strong profitability with 7.63% net income margin and exceptional ROE of 42.6%, though revenue growth remains modest. Recent earnings beats and positive analyst coverage highlight operational strength amid resilient airfreight demand and efficiency initiatives.

While valuation multiples appear elevated (P/E 28.2), consistent earnings outperformance and institutional interest support upside potential. Key risks include freight market volatility and competitive pressures. The consensus price target of $179.43 suggests modest downside from current levels, requiring careful risk-reward assessment.

Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.

LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.